MSB 0.91% $1.11 mesoblast limited

Ann: FDA Supports Accelerated Approval Pathway for Heart Failure, page-419

  1. 798 Posts.
    lightbulb Created with Sketch. 93
    I would suggest you reading this short paper and spare us from repeating nonsense about post hoc analysis.

    https://journals.lww.com/transplantjournal/fulltext/2015/01150/post_hoc_analyses__after_the_facts.8.aspx





    Last edited by Leo65: 18/03/24
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.